News
December 13, 2024

IU announces $138 million Lilly Endowment grant, launches partnership to accelerate bioscience innovation

Regenstrief one of the partners expected to drive advancements and commercialization in biosciences 

Regenstrief Institute will partner with Indiana University and other key bioscience organizations in the state to make significant advances in human health and help make Indiana a global leader in bioscience innovation by establishing the IU Launch Accelerator for Biosciences, known as IU LAB, at the 16 Tech Innovation District in Indianapolis. 

“IU LAB will play a critical role in advancing life and biosciences innovation to address our state’s most critical health challenges,” said Rachel Patzer, PhD, MPH, Regenstrief president and CEO. Through its efforts to translate research into practice, this partnership will lead to better health outcomes and improved health care across Indiana.”  

View the complete press release on Indiana University’s webpage 

Partners

Related News

Kathleen Unroe, M.D.

Barriers to Discharge for Nursing Home Residents With Serious Mental Illness

Published in the JAMA Network Open. Here is a link to the article. Regenstrief Institute authors: Kathleen T. Unroe,

Validation of a MIND diet screener in older adults

Published in Alzheimer’s & Dementia Journal. Here is a link to the article. Regenstrief Institute author: Daniel O. Clark,

Fairbanks, Lilly, Regenstrief and Indiana employers collaborate to study obesity medications’ impact

Fairbanks, Lilly, Regenstrief and Indiana employers collaborate to study obesity medications’ impact

INDIANAPOLIS — Researchers from the Fairbanks School of Public Health at Indiana University Indianapolis have launched a first-of-its-kind study

Music for the brain: Study tests the effect of slow-tempo relaxing music to address delirium in critically ill older adults

Music for the brain: Study tests the effect of slow-tempo relaxing music to address delirium in critically ill older adults

Findings support longer-duration or targeted approaches A multi-center randomized controlled trial with critically ill adults aged 50 years and